GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

VaxCell Biotherapeutics Co 323990.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

4,835

+29.97%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About VaxCell Biotherapeutics Co

Its shares trade on KOSDAQ under the ticker 323990.KQ. It has been listed since 22 September 2020. In the fiscal year to 31 December 2025, it reported revenue of ₩7.06bn and a net loss of ₩13.34bn. At that date it held total assets of ₩66.90bn and shareholders' equity of ₩61.13bn.

Vaxcell-Bio Therapeutics develops anti-cancer therapeutics. The company is headquartered in Hwasun, Jeollanam-Do. The company went IPO on 2020-09-22. The firm's pipeline consists of the Vax-NK natural killer cell anti-cancer immunotherapy platforms, the Vax-DC dendritic cell anti-cancer immunotherapy platforms, and the Vax-CAR series next-generation advanced anti-cancer immunotherapy platforms. In addition, the Company manufactures and sells cytokine-based boxleukin-15, an anticancer immunotherapy exclusively for dogs. The firm sells its products in domestic and overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
22 Sept 2020
Employees
54

Leadership

Pay as last reported

  • Mr. Seong Chang JungNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Hwasun, Jeollanam-Do with 54 employees
  • Offers multiple anti-cancer immunotherapy platforms including Vax-NK, Vax-DC, and Vax-CAR
  • Sells cytokine-based boxleukin-15 for canine cancer treatment

Weaknesses

  • IPO occurred in 2020-09-22, indicating relatively recent market entry
  • Limited employee count of 54 suggests potential resource constraints
  • Reliance on a single industry sector (Biotechnology) for revenue

Opportunities

  • Expansion into overseas markets for existing products
  • Potential growth in anti-cancer immunotherapy platforms
  • Opportunity to develop additional products in the canine cancer treatment segment

Threats

  • Competition in the biotechnology sector for anti-cancer therapies
  • Dependence on a narrow product portfolio for revenue generation
  • Regulatory challenges in the healthcare industry

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.